Ebara Corporation GAAP EPS of ¥73.48, revenue of ¥490.76B; updates FY 2026 outlook
财报/业绩新闻：Ebara Corporation GAAP EPS of ¥73.48, revenue of ¥490.76B; updates FY 2026 outlook 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
Market news
用期权视角读懂市场新闻
自动聚合美股、财报、宏观和热门标的新闻，固化为本站本地摘要页，并提取相关 ticker、中文摘要和期权研究提示。
Latest feed
财报新闻第 68 页
当前只显示财报分类的本地新闻摘要，分页和跳转会保留这个分类。
1247分类新闻68 / 104当前页
MS& AD Insurance GAAP EPS of ¥226.82, revenue of ¥1686.19B; reaffirms FY 2027 outlook
财报/业绩新闻：MS& AD Insurance GAAP EPS of ¥226.82, revenue of ¥1686.19B; reaffirms FY 2027 outlook 相关标的：MS。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
HawkEye 360 outlines $215M-$220M 2026 revenue outlook while targeting 10-minute revisit and latency in 2-3 years
财报/业绩新闻：HawkEye 360 outlines $215M-$220M 2026 revenue outlook while targeting 10-minute revisit and latency in 2-3 years 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
Health In Tech reaffirms $45M-$50M 2026 revenue guidance while preparing HitRix launch in the second half
财报/业绩新闻：Health In Tech reaffirms $45M-$50M 2026 revenue guidance while preparing HitRix launch in the second half 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
AmpliTech outlines 2026 priorities while declining to reaffirm $50M full-year revenue guidance amid deployment timing shifts
财报/业绩新闻：AmpliTech outlines 2026 priorities while declining to reaffirm $50M full-year revenue guidance amid deployment timing shifts 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
Blaize forecasts $40M-$43M 2026 revenue amid Starshine reserve and memory inflation
财报/业绩新闻：Blaize forecasts $40M-$43M 2026 revenue amid Starshine reserve and memory inflation 相关标的：SPY, QQQ。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
Rekor targets adjusted EBITDA profitability in H2 2026 as GoSecure expands into audio
财报/业绩新闻：Rekor targets adjusted EBITDA profitability in H2 2026 as GoSecure expands into audio 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter
财报/业绩新闻：Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
Caliber projects $18M-$22M 2026 revenue while expanding tokenization to an initial ~$100M slate of managed assets
财报/业绩新闻：Caliber projects $18M-$22M 2026 revenue while expanding tokenization to an initial ~$100M slate of managed assets 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
AudioEye expects over $15M run rate adjusted EBITDA by end of 2026 as it raises full-year adjusted EBITDA guidance to at least $12.7M
财报/业绩新闻：AudioEye expects over $15M run rate adjusted EBITDA by end of 2026 as it raises full-year adjusted EBITDA guidance to at least $12.7M 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
FocalTherics reiterates $50M-$54M 2026 HIFU revenue outlook as it closes $40M equity offering
财报/业绩新闻：FocalTherics reiterates $50M-$54M 2026 HIFU revenue outlook as it closes $40M equity offering 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。
Newsmax reiterates $212M-$216M 2026 revenue guidance while targeting about $16M in international licensing fees
财报/业绩新闻：Newsmax reiterates $212M-$216M 2026 revenue guidance while targeting about $16M in international licensing fees 暂未识别到明确 ticker，适合作为宏观或行业背景观察。
财报类新闻优先检查近月 IV、expected move、财报后波动压缩和价差流动性。